Impact of triplicated DYRK1A on neurogenesis and intellectual disability in down syndrome and therapeutic potential

Down syndrome (DS), caused by trisomy 21 (T21), affects approximately 1 in 700 live births and is characterized by a wide spectrum of features, including cognitive impairment, craniofacial abnormalities, congenital heart defects, and early-onset Alzheimer disease (EOAD). Among the ~364 protein-coding genes triplicated on HSA21, DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1A) has emerged as a key contributor to neurodevelopmental deficits. This review summarizes the neurogenetic consequences of DYRK1A triplication, its interactions with other genes, and therapeutic strategies targeting its overexpression.

Genetic Consequences of Cognitive Impairment
Individuals with DS exhibit global brain volume reduction, particularly in the frontal and temporal lobes, hippocampus, and cerebellum. Impaired neurogenesis, synaptogenesis, and synaptic transmission lead to learning and memory deficits. DS mouse models (e.g., Ts65Dn, Ts1Yah) recapitulate these phenotypes, showing reduced neuronal density, dendritic spine abnormalities, and impaired long-term potentiation (LTP). While the Down syndrome critical region (DSCR) on 21q22 is necessary for cognitive phenotypes, it is not sufficient, indicating contributions from multiple trisomic genes.

Influence of Sex and APOE on AD Pathogenesis
Sex differences in AD risk among DS individuals remain controversial. Some studies suggest women with DS have higher p-tau burden and faster cognitive decline, while others report no sex dimorphism. The APOE ε4 allele, the strongest genetic risk factor for AD, may interact with sex to influence disease penetrance. Female APOE ε4 carriers show greater tau susceptibility, earlier symptom onset, and smaller hippocampal volumes compared to male carriers. Homozygous ε4 individuals exhibit near-full penetrance of AD pathology, with striking biomarker similarities to DSAD and autosomal dominant AD.

Triplicated DYRK1A in Neurogenesis and Brain Development
DYRK1A is a dual-specificity kinase that autophosphorylates tyrosine and phosphorylates serine/threonine residues on numerous substrates. Overexpression (1.5-fold) in DS disrupts neurogenesis by:

• Cell cycle dysregulation: DYRK1A phosphorylates Cyclin D1 (Thr286) and stabilizes p27Kip1 (Ser10), promoting premature G1/G0 exit and reducing neural progenitor pools.

• DREAM complex assembly: DYRK1A phosphorylates LIN52 (Ser28), inducing quiescence and cell cycle exit.

• NOTCH and NFAT pathways: DYRK1A represses NOTCH signaling (promoting differentiation) and synergizes with RCAN1 to inhibit calcineurin-NFAT signaling, affecting neuronal development and survival.

• Synaptic function: DYRK1A phosphorylates Dynamin1, synapsin, and MUNC18-1, disrupting vesicle trafficking and neurotransmission.

DYRK1A and Alzheimer Disease
DYRK1A contributes to AD pathology by:

• Tau hyperphosphorylation: DYRK1A primes tau at Ser202/Thr212, facilitating GSK3β-mediated phosphorylation and neurofibrillary tangle formation.

• APP processing: DYRK1A phosphorylates APP at Thr668, promoting amyloidogenic pathway and Aβ production.

• Neprilysin regulation: DYRK1A downregulates the Aβ-degrading enzyme neprilysin, exacerbating Aβ accumulation.

• Neuroinflammation: DYRK1A activates STAT3 and other pro-inflammatory pathways.

Gene and Protein Interactions
DYRK1A interacts with over 35 protein partners, including SIRT1 (regulating stress responses), p53 (forming a negative feedback loop), and CAMK2 (affecting LTP). It also regulates transcription factors such as CREB, STAT3, and GLI1. Upregulation of other HSA21 genes (APP, RCAN1, CBS, OLIG2) synergizes with DYRK1A to exacerbate neurodegeneration. Trisomy also activates interferon pathways, contributing to chronic neuroinflammation.

Therapeutic Targets for DYRK1A Inhibition
Numerous DYRK1A inhibitors have been explored, primarily ATP-competitive agents with variable specificity:

Natural Products:

• EGCG (epigallocatechin gallate): From green tea; non-competitive inhibitor (IC50 330 nM). Clinical trials (TESDAD) showed modest cognitive improvements, but outcomes vary with age, dose, and treatment duration. Prenatal EGCG rescued some neurodevelopmental defects but raised safety concerns.

• Harmine: β-carboline alkaloid (IC50 80 nM) but lacks kinase selectivity and has hallucinogenic effects.

• Breitfussin C: Marine compound; reduces p27 phosphorylation and cell cycle progression.

• Aristolactam BIII: Natural alkaloid (IC50 9.67 nM); rescues cognitive and neurological phenotypes in DS models.

• Leucettines: Marine sponge-derived; leucettine L41 improved memory in three DS mouse models and is in Phase I trials (NCT06206824).

Synthetic Compounds:

• INDY, FINDY, F-DANDY: Early DYRK1A inhibitors; some rescued neurodevelopmental defects.

• KuFal194: Improved Purkinje cell organization in zebrafish DS models.

• SM07883: Oral, brain-penetrant inhibitor (IC50 1.6 nM); reduces tau pathology and neuroinflammation; Phase I completed.

• Silmitasertib (CX-4945): ATP-competitive; inhibits tau hyperphosphorylation in DS mice.

• PST-001: Highly selective, orally available, BBB-penetrant; improved fear conditioning in Ts65Dn mice.

• DYR291: Hybrid structure; improved memory in 3xTg-AD mice.

Other Strategies:

• Antisense oligonucleotides (ASOs): Target DYRK1A mRNA to reduce overexpression; FDA-approved ASOs for other neurological disorders suggest potential.

• Genetic inactivation: CRISPR/Cas9 editing or XIST-mediated silencing of the extra HSA21 in iPSCs offers a curative approach.

• GABAergic/glutamatergic modulators: Antagonists (e.g., Ro25-6981) and fluoxetine improved hippocampal LTP and cognition in DS models.

Overall Outcome and Future Challenges
Despite promising preclinical data, no DYRK1A inhibitor has yet achieved regulatory approval for DS. Key challenges include:

• Variable DYRK1A expression across developmental stages, tissues, and sex

• Lack of high-specificity inhibitors without off-target effects

• Limited BBB penetration of many compounds

• Inconsistent results from EGCG trials due to formulation and dosing heterogeneity

• Need for biomarkers to guide patient selection and monitor response

Future directions include:

• Advanced computational drug discovery (AI, machine learning)

• Combination therapies targeting multiple pathways (e.g., GABAergic modulation + DYRK1A inhibition)

• Gene-editing approaches for permanent correction

• Investigation of sexual dimorphism and APOE interactions to personalize treatment

Conclusions
Triplicated DYRK1A plays a central role in the neurodevelopmental deficits and early-onset Alzheimer disease in Down syndrome. Its overexpression disrupts cell cycle regulation, synaptic plasticity, neurotransmission, and multiple signaling pathways. While numerous inhibitors have shown promise in preclinical models, translation to clinical practice requires improved specificity, safety, and standardized protocols. Understanding the complex interactions of DYRK1A with other trisomic genes, sex, and APOE status will be critical for developing effective, personalized therapies to improve cognitive function and quality of life in individuals with DS.

Full text

https://www.xiahepublishing.com/1555-3884/GE-2025-00051

The study was recently published in the Gene Expression.

Gene Expression (GE) is an open-access journal. It was launched in 1991 by Chicago Medical School Press, and transferred to Cognizant Communication Corporation in 1994. From August 2022, GE is published by Xia & He Publishing Inc.   

GE publishes peer-reviewed and high-quality original articles, reviews, editorials, commentaries, and opinions on its primary research topics including cell biology, molecular biology, genes, and genetics, especially on the cellular and molecular mechanisms of human diseases. 

GE has been indexed in Medline (1991-2021), Scopus, Biological Abstracts, Biosis Previews, ProQuest, etc.

Follow us on X: @xiahepublishing

Follow us on LinkedIn: Xia & He Publishing Inc.